相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment
Oshrat Hershkovitz-Rokah et al.
CANCER LETTERS (2015)
Making Sense of Anti-Sense Data
Didier Y. R. Stainier et al.
DEVELOPMENTAL CELL (2015)
Structure, Function, and Resistance in Chronic Myeloid Leukemia
Jerald Radich
CANCER CELL (2014)
Proinflammatory Signaling Regulates Hematopoietic Stem Cell Emergence
Raquel Espin-Palazon et al.
CELL (2014)
The COBLL1 C allele is associated with lower serum insulin levels and lower insulin resistance in overweight and obese children
Rosellina Margherita Mancina et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2013)
Numbl inhibits glioma cell migration and invasion by suppressing TRAF5-mediated NF-κB activation
Tao Tao et al.
MOLECULAR BIOLOGY OF THE CELL (2012)
Noncanonical NF-?B Signaling Regulates Hematopoietic Stem Cell Self-Renewal and Microenvironment Interactions
Chen Zhao et al.
STEM CELLS (2012)
p47 negatively regulates IKK activation by inducing the lysosomal degradation of polyubiquitinated NEMO
Yuri Shibata et al.
NATURE COMMUNICATIONS (2012)
Aberrant microRNA expression and its implications in the pathogenesis of leukemias
Sadegh Babashah et al.
CELLULAR ONCOLOGY (2012)
Genes Associated With Prognosis After Surgery For Malignant Pleural Mesothelioma Promote Tumor Cell Survival In Vitro
Gavin J. Gordon et al.
BMC CANCER (2011)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Amie S. Corbin et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation
Neesar Ahmed et al.
NATURE IMMUNOLOGY (2011)
Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib
T-M Kim et al.
BLOOD CANCER JOURNAL (2011)
Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation
A. R. R. Forrest et al.
LEUKEMIA (2010)
Insights into the stem cells of chronic myeloid leukemia
I. Sloma et al.
LEUKEMIA (2010)
Regulation of myeloid leukaemia by the cell-fate determinant Musashi
Takahiro Ito et al.
NATURE (2010)
Hypoxia Activates NF-κB-Dependent Gene Expression Through the Canonical Signaling Pathway
Kathryn M. Oliver et al.
ANTIOXIDANTS & REDOX SIGNALING (2009)
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
David Masiello et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy
Hyun-Gyung Goh et al.
LEUKEMIA & LYMPHOMA (2009)
Kinase drug discovery approaches in chronic myeloproliferative disorders
C. Kumar et al.
ONCOGENE (2009)
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford et al.
BLOOD (2008)
BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair
Kimberly Cramer et al.
CANCER RESEARCH (2008)
IκB kinase β inhibition induces cell death in Imatinib-resistant and T315I Dastinib-resistant BCR-ABL+ cells
Elizabeth A. Duncan et al.
MOLECULAR CANCER THERAPEUTICS (2008)
TRIM30α negatively regulates TLR-mediated NF-κB activation by targeting TAB2 and TAB3 for degradation
Mude Shi et al.
NATURE IMMUNOLOGY (2008)
Chronic myeloid leukaemia as a model of disease evolution in human cancer
Junia V. Melo et al.
NATURE REVIEWS CANCER (2007)
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia
Simona Soverini et al.
CLINICAL CANCER RESEARCH (2006)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Gene expression signatures associated with the resistance to imatinib
Y-J Chung et al.
LEUKEMIA (2006)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes et al.
BLOOD (2006)
Gene expression changes associated with progression and response in chronic myeloid leukemia
JP Radich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Targeting NF-κB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells
C Frelin et al.
BLOOD (2005)
Specific targeted therapy of chronic myelogenous leukemia with imatinib
MWN Deininger et al.
PHARMACOLOGICAL REVIEWS (2003)
Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back
N von Bubnoff et al.
LEUKEMIA (2003)
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
FX Mahon et al.
BLOOD (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
NJ Donato et al.
BLOOD (2003)
NF-κB regulation in the immune system
QT Li et al.
NATURE REVIEWS IMMUNOLOGY (2002)
NF-κB in cancer:: From innocent bystander to major culprit
M Karin et al.
NATURE REVIEWS CANCER (2002)
Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the Abl inhibitor STI571
C Gambacorti-Passerini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
